Some existing anti-cancer drugs may act in part by targeting RNA

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells. The research offers another approach for tackling diseases that have been considered "undruggable," including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers.

"Known drugs made in the era when RNAs were not considered drug targets are, in fact, binding RNA, and causing some of the drug's effects by modulating targets that were not previously considered," says chemist Matthew D. Disney, PhD, professor on the Florida campus of Scripps Research, who led the study. "We found broad drug classes that bind RNA. There is reason to believe that not only could known drugs bind RNA in a disease setting, but there is more evidence that one should consider RNA as a target in drug-discovery efforts."

While the universe of human proteins consists of about 20,000 varieties, the universe of human RNAs is closer to 200,000, potentially offering other effective opportunities to intervene, Disney says.

The paper, "Approved Anti-Cancer Drugs Target Oncogenic Non-Coding RNAs," appears in the journal Cell Chemical Biology.

Most drugs on the market today come in the form of pills that contain active small molecule medicines. Through a process called structure-based drug design, chemists optimize such small molecule drugs to bind selectively and tightly to their biologic targets. The target is generally the pocket of a protein important in disease progression.

But there are limitations to small molecules. Because proteins are large and contain many folds and crevasses, sometimes key disease-driving areas are inaccessible to small molecule drugs. This problem has inspired Disney and other researchers to take a closer look at the roots of diseases. Because RNAs are involved in assembling proteins within cells, some have hypothesized that "undruggable" diseases could be modified prior to protein fabrication, at the RNA level.

Disney says he has encountered skepticism about the value of pursuing RNA-binding small molecule therapeutics. The thought was RNAs presented too challenging a target due to their size, movement, changeability and uncertain specificity. RNAs are shape-shifters, and generally thought to lack clearly defined structures to which a small molecule drug could obviously bind. Yet all along, as the new study shows, existing drugs have been doing just that - and binding defined pockets in an RNA - Disney says.

To explore his hypothesis, Disney devised a system for rapidly testing a large library of existing drugs against a wide variety of RNA molecules. He calls his testing system AbsorbArray.

"Basically, we figured out a way in which we could test millions of combinations of small molecule medicines and RNA folds that bind to each other," Disney says.

With AbsorbArray, the researchers identified the three drugs that bound to one type of microRNA and found they were microRNAs involved in every cancer. The drugs, called kinase- and topoisomerase-inhibitors, interfere with expression of a microRNA called miR-21. In further testing, it became clear that interfering with that microRNA prevented cancer cells from invading tissue.

"This data supports the hypothesis that very average-looking small molecule drugs can target RNA," Disney says.

Conducting the experiment required using a library of known small molecule drugs, and testing them against another library, of pre-messenger RNA, a process Disney called two-dimensional combinatorial screening. He was assisted in that effort by Arnab K. Chatterjee, PhD, at the California Institute for Biomedical Research (Calibr), a division of Scripps Research, which supplied the RNA splicing modulator library for the experiments.

"What is particularly interesting to me as a chemist is how existing compounds that have been tested in the clinic and optimized on one protein target may have additional novel activities in targeting RNA as well," Chatterjee says.

Looking forward, the next question is whether the selectivity and drug-like properties of these anti-cancer compounds will extend to diseases other than cancers, Chatterjee says.

In recent years, the Disney lab has found RNA-binding molecules applicable to many diseases, including ALS, myotonic dystrophy type 2, triple-negative breast cancer, inflammation, cystic fibrosis, Alport syndrome and more. The AbsorbArray findings underscore the likely value of continuing to move these disease-relevant RNA-binding compounds toward a clinical setting, Disney said.

"Drugs that patients take every day apparently target RNA, which is only recently being thought of as a target for small molecule medicines," Disney says. "As new RNAs are found to cause disease, routine medicines may be identified to target them. This would change the perception of RNAs as an afterthought in drug discovery and bring them to the forefront."

Other authors of the study, "Approved Anti-Cancer Drugs Target Oncogenic Non-Coding RNAs," include Sai Pradeep Velagapudi, Matthew G. Costales, Balayeshwanth R. Vummidi, Yoshio Nakai, Alicia J. Angelbello, Tuan Tran, Hafeez S. Haniff, Yasumasa Matsumoto, Zi Fu Wang and Jessica L. Childs-Disney of Scripps Research and Arnab K. Chatterjee of the California Institute for Biomedical Research (CALIBR).

This work was supported by the Scheller Graduate Student Fellowship, a Swiss National Science Foundation Early Postdoc Mobility Fellowship, and the National Institutes of Health (grant 5R01GM097455).

"Drugs that patients take every day apparently target RNA, which is only recently being thought of as a target for small molecule medicines," Disney says. "As new RNAs are found to cause disease, routine medicines may be identified to target them. This would change the perception of RNAs as an afterthought in drug discovery and bring them to the forefront."

Sai Pradeep Velagapudi, Matthew G Costales, Balayeshwanth R Vummidi, Yoshio Nakai, Alicia J Angelbello, Tuan Tran, Hafeez S Haniff, Yasumasa Matsumoto, Zi Fu Wang, Arnab K Chatterjee, Jessica L Childs-Disney, Matthew D Disney.
Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs.
Cell Chemical Biology. doi: 10.1016/j.chembiol.2018.05.015.

Most Popular Now

US FDA grants Lynparza Orphan Drug Designation for…

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by ...

FDA approves new drug to treat influenza

The U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older...

Eating leafy greens could help prevent macular deg…

A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-relat...

Alcon to develop SMART Suite digital health platfo…

Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is design...

Amgen launches AMGEVITATM (biosimilar adalimumab) …

Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimum...

Boehringer Ingelheim increases awareness of health…

Boehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 20...

Targeted drugs for advanced cancer move from speci…

Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutation...

Novartis 5-year data in psoriatic arthritis and an…

Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and ...

FDA approves asthma indication for Dupixent® (dupi…

The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and old...

Largest census of cancer genes to help understand …

Researchers at the Wellcome Sanger Institute have created the first comprehensive summary of all genes known to be involved in human cancer, the "Cancer Gene Census". Des...

Diets rich in fish oil could slow the spread and g…

Omega-3 fatty acids, such as those typically contained in fish oil, may suppress the growth and spread of breast cancer cells in mice. This is according to a new study in...

Novartis announces clinical collaboration with Pfi…

Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer comp...